Steve Projan is the head of Infectious Diseases & Vaccines Innovative Medicines unit (iMED) at MedImmune, leading a cross-functional team dedicated to the therapeutic area strategy, prioritization and advancement of the company’s infectious disease and vaccine portfolio.
Steve joined MedImmune in 2010 as senior vice president of research and development and head of the Infectious Diseases & Vaccines iMED.
Prior to joining MedImmune, Steve served as vice president and global head of Infectious Diseases at Novartis. He previously spent 15 years at Wyeth in roles of increasing responsibility, with his last post as vice president and head of Biological Technologies. During his time at Wyeth, he started the Biologics Discovery Group (covering all therapeutic areas) and initiated multiple collaborations and partnerships, most notably with Cambridge Antibody Technology (now a part of MedImmune/AZ). Prior to his work in the industry, Steve spent 14 years at the Public Health Research Institute and presently has over 110 publications to his credit.
Steve received a bachelor of science from MIT, and, from Columbia University, a master of arts and philosophy in biological sciences and a doctorate in molecular genetics.